Basel, 7 December 2012
Changes in Roche Board of Directors
At its December meeting, the Board of Directors (BoD) of Roche Holding recommended proposals for approval by the AGM, scheduled for 5 March 2013. Prof. Dr. Bruno Gehrig (born 1946, Member of the Board since 2004) and Lodewijk J.R. de Vink (born 1946, Member of the Board since 2004) have announced that they will not stand for re-election to the Board of Directors. The Board of Directors would like to thank both Members for their long and valuable contribution to the successful continuing development of Roche.
Dr. Severin Schwan (born 1967), CEO of Roche, will be proposed as a new member to the Board of Directors.
|Name (year of birth)||Board member since|
|Dr. Andreas Oeri ( 1949)||1996|
|Prof. Dr. Pius Baschera (1950)||2007|
|Paul Bulcke (1954)||2011|
|William M. Burns (1947)||2010|
|Dr. Christoph Franz (1960)||2011|
|Dr. DeAnne Julius (1949)||2002|
|Dr. Arthur D. Levinson (1950)||2010|
|Peter R. Voser (1958)||2011|
|Prof. Dr. Beatrice Weder di Mauro (1965)||2006|
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.